Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Luxury Car Sales in the Middle East Take a Hit Amid Iran War 
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs 
Elon Musk Ties SpaceX IPO Access to Mandatory Grok AI Subscriptions 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Britain Courts Anthropic Amid US Defense Department Dispute 
CTOC Adds 3,000 Doctors, 500 Hospitals Ahead of Liquidity Push 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
TUSTIN, Calif., July 07, 2017 -- Peregrine Pharmaceuticals, Inc. (NASDAQ:PPHM) (NASDAQ:PPHMP), a biopharmaceutical company committed to improving patient lives by manufacturing high quality products for biotechnology and pharmaceutical companies and advancing its proprietary R&D pipeline, today announced that it will report financial results for the quarter and fiscal year (FY) ended April 30, 2017 on July 14, 2017 after market close, and will host a conference call and webcast at 1:30 PM PDT (4:30 PM EDT). Peregrine's senior management will discuss financial results for the quarter and FY ended April 30, 2017 and review recent corporate developments.
To listen to the live webcast, or access the archived webcast, please visit: http://ir.peregrineinc.com/events.cfm.
To listen to the conference call, please dial (877) 312-5443 or (253) 237-1126 and request the Peregrine Pharmaceuticals call.
About Peregrine Pharmaceuticals, Inc.
Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company committed to improving the lives of patients by delivering high quality pharmaceutical products through its contract development and manufacturing organization (CDMO) services and through advancing and licensing its investigational immunotherapy and related products. Peregrine's in-house CDMO services, including cGMP manufacturing and development capabilities, are provided through its wholly-owned subsidiary Avid Bioservices, Inc. (www.avidbio.com), which provides development and biomanufacturing services for both Peregrine and third-party customers. The company is also working to evaluate its lead immunotherapy candidate, bavituximab, in combination with immune stimulating therapies for the treatment of various cancers, and developing its proprietary exosome technology for the detection and monitoring of cancer. For more information, please visit www.peregrineinc.com.
Contacts: Stephanie Diaz (Investors) Vida Strategic Partners 415-675-7401 [email protected] Tim Brons (Media) Vida Strategic Partners 415-675-7402 [email protected]
